Renal medullary carcinoma and ABL gene amplification

Lijo Simpson, Xiang He, Michael Pins, Xiaoke Huang, Steven C. Campbell, Ximing J. Yang, Elizabeth J. Perlman, Raymond Bergan

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Purpose: We characterized the clinical course of renal medullary carcinoma (RMC) and performed an expanded analysis of BCR-ABL. Materials and Methods: The literature was searched for all reports of RMC. New cases at Northwestern University are described and relevant clinical information was abstracted. BCR and ABL genes, and ABL protein were evaluated by fluorescence in situ hybridization and immunohistochemical analysis, respectively. Results: A total of 95 cases were identified. Mean age at diagnosis was 19 years, the male-to-female ratio was 1.9:1.0, 90% of all patients were black, 98% had an abnormality in a least 1 hemoglobin gene (ie sickle cell trait, SC disease or sickle cell disease) and mean survival was 19 weeks. Two patients (3%) without metastasis were long-term survivors. The response to chemotherapy was poor. One patient treated with thalidomide survived for 52 weeks. The ABL gene was amplified a mean ± SEM of 1.9 ± 0.1-fold in all 3 cases evaluated, while ABL protein was increased in 2 of 3 evaluated. No evidence of BCR-ABL translocation was detected. Conclusions: RMC is typically seen in young individuals with the sickle cell trait. It is diagnosed when metastatic, is not responsive to systemic therapy and rapidly causes death. Because cure appears possible with early diagnosis, increased awareness of the disease could make an impact. The use of thalidomide or newer anti-angiogenesis agents should be considered for advanced disease. The role of ABL amplification with respect to etiology and as a therapeutic target should be investigated further.

Original languageEnglish (US)
Pages (from-to)1883-1888
Number of pages6
JournalJournal of Urology
Volume173
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Medullary Carcinoma
Gene Amplification
Sickle Cell Trait
Thalidomide
Kidney
Hemoglobin SC Disease
Sickle Cell Anemia
Fluorescence In Situ Hybridization
Genes
Survivors
Early Diagnosis
Cause of Death
Hemoglobins
Proteins
Neoplasm Metastasis
Drug Therapy
Survival
Therapeutics

Keywords

  • Gene expression
  • Imatinib
  • Kidney
  • Kidney neoplasms
  • Sickle cell trait

ASJC Scopus subject areas

  • Urology

Cite this

Simpson, L., He, X., Pins, M., Huang, X., Campbell, S. C., Yang, X. J., ... Bergan, R. (2005). Renal medullary carcinoma and ABL gene amplification. Journal of Urology, 173(6), 1883-1888. https://doi.org/10.1097/01.ju.0000158448.56888.09

Renal medullary carcinoma and ABL gene amplification. / Simpson, Lijo; He, Xiang; Pins, Michael; Huang, Xiaoke; Campbell, Steven C.; Yang, Ximing J.; Perlman, Elizabeth J.; Bergan, Raymond.

In: Journal of Urology, Vol. 173, No. 6, 06.2005, p. 1883-1888.

Research output: Contribution to journalArticle

Simpson, L, He, X, Pins, M, Huang, X, Campbell, SC, Yang, XJ, Perlman, EJ & Bergan, R 2005, 'Renal medullary carcinoma and ABL gene amplification', Journal of Urology, vol. 173, no. 6, pp. 1883-1888. https://doi.org/10.1097/01.ju.0000158448.56888.09
Simpson L, He X, Pins M, Huang X, Campbell SC, Yang XJ et al. Renal medullary carcinoma and ABL gene amplification. Journal of Urology. 2005 Jun;173(6):1883-1888. https://doi.org/10.1097/01.ju.0000158448.56888.09
Simpson, Lijo ; He, Xiang ; Pins, Michael ; Huang, Xiaoke ; Campbell, Steven C. ; Yang, Ximing J. ; Perlman, Elizabeth J. ; Bergan, Raymond. / Renal medullary carcinoma and ABL gene amplification. In: Journal of Urology. 2005 ; Vol. 173, No. 6. pp. 1883-1888.
@article{2364dd78db7f41d1869de05d91905005,
title = "Renal medullary carcinoma and ABL gene amplification",
abstract = "Purpose: We characterized the clinical course of renal medullary carcinoma (RMC) and performed an expanded analysis of BCR-ABL. Materials and Methods: The literature was searched for all reports of RMC. New cases at Northwestern University are described and relevant clinical information was abstracted. BCR and ABL genes, and ABL protein were evaluated by fluorescence in situ hybridization and immunohistochemical analysis, respectively. Results: A total of 95 cases were identified. Mean age at diagnosis was 19 years, the male-to-female ratio was 1.9:1.0, 90{\%} of all patients were black, 98{\%} had an abnormality in a least 1 hemoglobin gene (ie sickle cell trait, SC disease or sickle cell disease) and mean survival was 19 weeks. Two patients (3{\%}) without metastasis were long-term survivors. The response to chemotherapy was poor. One patient treated with thalidomide survived for 52 weeks. The ABL gene was amplified a mean ± SEM of 1.9 ± 0.1-fold in all 3 cases evaluated, while ABL protein was increased in 2 of 3 evaluated. No evidence of BCR-ABL translocation was detected. Conclusions: RMC is typically seen in young individuals with the sickle cell trait. It is diagnosed when metastatic, is not responsive to systemic therapy and rapidly causes death. Because cure appears possible with early diagnosis, increased awareness of the disease could make an impact. The use of thalidomide or newer anti-angiogenesis agents should be considered for advanced disease. The role of ABL amplification with respect to etiology and as a therapeutic target should be investigated further.",
keywords = "Gene expression, Imatinib, Kidney, Kidney neoplasms, Sickle cell trait",
author = "Lijo Simpson and Xiang He and Michael Pins and Xiaoke Huang and Campbell, {Steven C.} and Yang, {Ximing J.} and Perlman, {Elizabeth J.} and Raymond Bergan",
year = "2005",
month = "6",
doi = "10.1097/01.ju.0000158448.56888.09",
language = "English (US)",
volume = "173",
pages = "1883--1888",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Renal medullary carcinoma and ABL gene amplification

AU - Simpson, Lijo

AU - He, Xiang

AU - Pins, Michael

AU - Huang, Xiaoke

AU - Campbell, Steven C.

AU - Yang, Ximing J.

AU - Perlman, Elizabeth J.

AU - Bergan, Raymond

PY - 2005/6

Y1 - 2005/6

N2 - Purpose: We characterized the clinical course of renal medullary carcinoma (RMC) and performed an expanded analysis of BCR-ABL. Materials and Methods: The literature was searched for all reports of RMC. New cases at Northwestern University are described and relevant clinical information was abstracted. BCR and ABL genes, and ABL protein were evaluated by fluorescence in situ hybridization and immunohistochemical analysis, respectively. Results: A total of 95 cases were identified. Mean age at diagnosis was 19 years, the male-to-female ratio was 1.9:1.0, 90% of all patients were black, 98% had an abnormality in a least 1 hemoglobin gene (ie sickle cell trait, SC disease or sickle cell disease) and mean survival was 19 weeks. Two patients (3%) without metastasis were long-term survivors. The response to chemotherapy was poor. One patient treated with thalidomide survived for 52 weeks. The ABL gene was amplified a mean ± SEM of 1.9 ± 0.1-fold in all 3 cases evaluated, while ABL protein was increased in 2 of 3 evaluated. No evidence of BCR-ABL translocation was detected. Conclusions: RMC is typically seen in young individuals with the sickle cell trait. It is diagnosed when metastatic, is not responsive to systemic therapy and rapidly causes death. Because cure appears possible with early diagnosis, increased awareness of the disease could make an impact. The use of thalidomide or newer anti-angiogenesis agents should be considered for advanced disease. The role of ABL amplification with respect to etiology and as a therapeutic target should be investigated further.

AB - Purpose: We characterized the clinical course of renal medullary carcinoma (RMC) and performed an expanded analysis of BCR-ABL. Materials and Methods: The literature was searched for all reports of RMC. New cases at Northwestern University are described and relevant clinical information was abstracted. BCR and ABL genes, and ABL protein were evaluated by fluorescence in situ hybridization and immunohistochemical analysis, respectively. Results: A total of 95 cases were identified. Mean age at diagnosis was 19 years, the male-to-female ratio was 1.9:1.0, 90% of all patients were black, 98% had an abnormality in a least 1 hemoglobin gene (ie sickle cell trait, SC disease or sickle cell disease) and mean survival was 19 weeks. Two patients (3%) without metastasis were long-term survivors. The response to chemotherapy was poor. One patient treated with thalidomide survived for 52 weeks. The ABL gene was amplified a mean ± SEM of 1.9 ± 0.1-fold in all 3 cases evaluated, while ABL protein was increased in 2 of 3 evaluated. No evidence of BCR-ABL translocation was detected. Conclusions: RMC is typically seen in young individuals with the sickle cell trait. It is diagnosed when metastatic, is not responsive to systemic therapy and rapidly causes death. Because cure appears possible with early diagnosis, increased awareness of the disease could make an impact. The use of thalidomide or newer anti-angiogenesis agents should be considered for advanced disease. The role of ABL amplification with respect to etiology and as a therapeutic target should be investigated further.

KW - Gene expression

KW - Imatinib

KW - Kidney

KW - Kidney neoplasms

KW - Sickle cell trait

UR - http://www.scopus.com/inward/record.url?scp=18744377728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744377728&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000158448.56888.09

DO - 10.1097/01.ju.0000158448.56888.09

M3 - Article

C2 - 15879768

AN - SCOPUS:18744377728

VL - 173

SP - 1883

EP - 1888

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -